Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of topical application of IDP-108 versus vehicle in treating patients with onychomycosis.


Options:
A: Inclusion Criteria:

* Subject having given her/his informed, written consent.

  * Subject cooperative and aware of the modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.
  * Subject being psychologically able to understand information and to give their/his/her consent.
  * Age: more than 18 years.
  * Subject with superficial onychomycosis on at least one great toenail or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement \<2/3 of the tablet).
  * Subject with positive KOH staining.
  * Subject having stopped any systemic antifungal treatment since at least 6 months before inclusion and/or any topical antifungal treatment since at least 3 months before inclusion.
  * Female subjects of childbearing potential should use an accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after study end.

Exclusion Criteria:

* Subject considered by the Investigator likely to be non-compliant with the protocol.
* Patient enrolled in another clinical trial during the test period.

  · Woman being pregnant, nursing or planning a pregnancy during the course of this study.
* Subject having a known allergy to one of the constituents of the tested products.
* Patient suffering from serious or progressive diseases (to investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology...
* Subject with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis...).
B: Inclusion Criteria:

* Diabetes
* Over 18 years old
* Clinically suspicion with microbiologic confirmation of onychomycosis
* Patient is at risk for diabetic foot ulcers defines as Simms score 1, 2 .

Exclusion Criteria:

* Patients without the microbiological confirmation of fungal nail infection
* Patients with an active or history of a diabetic foot ulcer
* Patients who used systemic or topical anti fungal agents during the preceding 3 months
* Patients with ischemic rest pain
* Patients with ankle brachial index \< 0.9
* Patients with a documented toe pressure below 50 mmHg
* Patients receiving dialysis, severe renal insufficiently (eGFR below 30 ml/min)
* Patients with an insufficient knowledge of the Dutch language to understand requirements of the study
* Patients with a dark skin color (Fitspatrick 4 and 5)
* Patients who uses immunosuppressive medication
* Patient suffering from nail psoriasis , lichen planus, or other abnormalities that could result in clinically abnormal toenails.
C: Inclusion Criteria:

* Clinically diagnosed onychomycosis of the target nail
* Presence of mild to moderate onychomycosis, defined as 20 - 50% of the area of the target nail being clinically affected
* Has a positive KOH examination from the target nail
* Has a positive dermatophyte culture from the target nail

Exclusion Criteria:

* Presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug
* Use of any systemic antifungal therapy within 4 weeks prior to the Screening visit or non-responsive to systemic antifungal therapy for onychomycosis
* Use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the Screening visit
* Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period
D: Inclusion Criteria:

* Clinically diagnosed onychomycosis of the target nail
* Presence of mild to moderate onychomycosis, defined as 20 - 50% of the area of the target nail being clinically affected
* Has a positive KOH examination from the target nail
* Has a positive dermatophyte culture from the target nail

Exclusion Criteria:

* Presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug
* Use of any systemic antifungal therapy within 4 weeks prior to the Screening visit or non-responsive to systemic antifungal therapy for onychomycosis
* Use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the Screening visit
* Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period

Answer: D